Fact CheckerSign in

NCT07363707CompletedPhase 4

A Study Between Dapagliflozin and Empagliflozin Effect on NAFLD in Patients With Type 2 Diabetes.

A Comparative Study of the Effect of Dapagliflozin Versus Empagliflozin ,Added to Metformin, on NAFLD in Patients With Type 2 Diabetes

Source: ClinicalTrials.gov · Last updated 3 Feb 2026

Brief summary (registry, in English)

The goal of this clinical trial is to learn if drugs Dapagliflozin and Empagliflozin work to treat NAFLD in Type 2 diabetes patients. It will also learn about the safety of drugs dapagliflozin and empagliflozin. The main questions it aims to answer are: Do drug dapagliflozin and empagliflozin lower the NAFLD degree for participants? What medical problems do participants have when taking the drugs dapagliflozin and empagliflozin? Researchers will compare drug dapagliflozin to empagliflozin to see which of them more effective to treat NAFLD. Participants will: Take drug dapagliflozin or empaglifloin every day for 6 months Visit the clinic once every 2 weeks for checkups and tests Keep a diary of their symptoms and the number of times they use a rescue inhaler

Status (registry)
Completed
Phase (registry)
Phase 4
Study type
Interventional
Enrollment
108 (actual)
First submitted
19 Dec 2025
Start date
1 May 2023
Primary completion date
27 Aug 2023
Lead sponsor
Beni-Suef University
NCT number
NCT07363707

What you commit to

  • Study type: Interventional · Phase 4
  • Participants enrolled: 108
  • From 1 May 2023 to the primary completion date, 27 Aug 2023
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Drugs that cause steatohepatitis

Other illness

  • People who have chronic liver disease,
  • Hepatitis C virus (HCV) patients or those treated for HCV,
  • History of autoimmune disease,

Other

  • and alcoholic patients will be excluded.

Who the study is looking for

  • Adults from 18 years old, male or female type 2 diabetic NAFLD patients.

Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Beni Suef University Hospital
Coordinator of this site? Confirm its status
CairoEgyptUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.